Altoida

Altoida is a pioneer in developing digital biomarkers of neurological conditions — including Alzheimer's disease — using augmented reality and machine learning. Founded in 2016 and headquartered in Washington, D.C., the company's proprietary Digital NeuroMarker Platform is grounded in over 20 years of scientific research published in peer-reviewed journals including Nature Digital Medicine. The platform uses a 10-minute tablet-based assessment to objectively evaluate cognitive health and function, enabling earlier detection of disease and scalable monitoring of progression and treatment response across clinical trials in 17 countries.